

# Clarissa S Gama

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8251631/publications.pdf>

Version: 2024-02-01

113  
papers

6,061  
citations

87888

38  
h-index

74163

75  
g-index

115  
all docs

115  
docs citations

115  
times ranked

6633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 74-80.	1.7	7
2	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	1.7	6
3	Accelerated aging signatures in subjects with schizophrenia and their unaffected siblings. <i>Journal of Psychiatric Research</i> , 2021, 139, 30-37.	3.1	4
4	Resveratrol prevents long-term structural hippocampal alterations and modulates interneuron organization in an animal model of ASD. <i>Brain Research</i> , 2021, 1768, 147593.	2.2	9
5	Risk of neutropenia among clozapine users and non-users: results from 5,847 patients. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	1.7	3
6	Sex influences in the preventive effects of N-acetylcysteine in a two-hit animal model of schizophrenia. <i>Journal of Psychopharmacology</i> , 2020, 34, 125-136.	4.0	26
7	Perceived childhood adversities: Impact of childhood trauma to estimated intellectual functioning of individuals with bipolar disorder. <i>Psychiatry Research</i> , 2019, 274, 345-351.	3.3	14
8	N-3 polyunsaturated fatty acids and clozapine abrogates poly I: C-induced immune alterations in primary hippocampal neurons. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 186-196.	4.8	14
9	Imaging Social and Environmental Factors as Modulators of Brain Dysfunction: Time to Focus on Developing Non-Western Societies. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 8-15.	1.5	14
10	Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 310-319.	2.6	21
11	Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging. <i>Schizophrenia Bulletin</i> , 2018, 44, 158-167.	4.3	35
12	White matter volume is decreased in bipolar disorder at early and late stages. <i>Trends in Psychiatry and Psychotherapy</i> , 2018, 40, 277-284.	0.8	9
13	The Relationship between Cytokines and Verbal Memory in Individuals with Schizophrenia and Their Unaffected Siblings. <i>NeuroImmunoModulation</i> , 2018, 25, 334-339.	1.8	7
14	Effects of N-acetylcysteine on amphetamine-induced sensitization in mice. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 169-173.	1.7	5
15	Volumetric brain magnetic resonance imaging predicts functioning in bipolar disorder: A machine learning approach. <i>Journal of Psychiatric Research</i> , 2018, 103, 237-243.	3.1	47
16	Cardiovascular risk and bipolar disorder: factors associated with a positive coronary calcium score in patients with bipolar disorder type 1. <i>Revista Brasileira De Psiquiatria</i> , 2018, 40, 163-168.	1.7	7
17	Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2018, 9, 241.	2.6	83
18	Mediator effects of parameters of inflammation and neurogenesis from a <i>N</i>-acetyl cysteine clinical-trial for bipolar depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 334-341.	2.1	16

#	ARTICLE	IF	CITATIONS
19	The Relationship of Intellectual Functioning and Cognitive Performance to Brain Structure in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw090.	4.3	37
20	Accumbens volumes are reduced among crack-cocaine users. <i>Neuroscience Letters</i> , 2017, 645, 86-89.	2.1	18
21	Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: Study of sex differences and brain oxidative alterations. <i>Behavioural Brain Research</i> , 2017, 331, 30-37.	2.2	66
22	Î±-Lipoic Acid as Adjunctive Treatment for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 697-701.	1.4	19
23	Anxiolytic properties of N -acetylcysteine in mice. <i>Behavioural Brain Research</i> , 2017, 317, 461-469.	2.2	26
24	Pinocembrin Provides Mitochondrial Protection by the Activation of the Erk1/2-Nrf2 Signaling Pathway in SH-SY5Y Neuroblastoma Cells Exposed to Paraquat. <i>Molecular Neurobiology</i> , 2017, 54, 6018-6031.	4.0	30
25	Carnosic Acid Protects Mitochondria of Human Neuroblastoma SH-SY5Y Cells Exposed to Paraquat Through Activation of the Nrf2/HO-1Axis. <i>Molecular Neurobiology</i> , 2017, 54, 5961-5972.	4.0	33
26	Serum concentrations of brain-derived neurotrophic factor in patients diagnosed with gender dysphoria undergoing sex reassignment surgery. <i>Trends in Psychiatry and Psychotherapy</i> , 2017, 39, 43-47.	0.8	4
27	Analyzing leukocyte telomere length in bipolar disorder: Authorsâ€™ reply. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 275-276.	1.7	1
28	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 281-286.	1.7	43
29	Cognition and functioning in bipolar depression. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 201-206.	1.7	22
30	Neurobiological underpinnings of bipolar disorder focusing on findings of diffusion tensor imaging: a systematic review. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 167-175.	1.7	28
31	Telomere length in subjects with schizophrenia, their unaffected siblings and healthy controls: Evidence of accelerated aging. <i>Schizophrenia Research</i> , 2016, 174, 39-42.	2.0	38
32	Hippocampus size does not correlate with body mass index in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 86-87.	1.7	4
33	Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia. <i>Anais Da Academia Brasileira De Ciencias</i> , 2015, 87, 1475-1486.	0.8	14
34	Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 121-125.	1.7	19
35	Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics. <i>Schizophrenia Research</i> , 2015, 168, 571-572.	2.0	2
36	Verbal episodic memory along the course of schizophrenia and bipolar disorder: A new perspective. <i>European Neuropsychopharmacology</i> , 2015, 25, 169-175.	0.7	31

#	ARTICLE	IF	CITATIONS
37	Treatment delay is associated with more episodes and more severe illness staging progression in patients with bipolar disorder. <i>Psychiatry Research</i> , 2015, 227, 372-373.	3.3	11
38	Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. <i>Journal of Affective Disorders</i> , 2015, 182, 64-69.	4.1	47
39	Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitroergic and neurotrophic mechanisms. <i>Schizophrenia Research</i> , 2015, 165, 163-170.	2.0	67
40	Right hippocampus size is negatively correlated with leptin serum levels in bipolar disorder. <i>Psychiatry Research</i> , 2015, 230, 719-721.	3.3	5
41	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 84-89.	1.8	16
42	Brain-derived neurotrophic factor and inflammatory markers in school-aged children with early trauma. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 360-368.	4.5	41
43	Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia. <i>Life Sciences</i> , 2015, 121, 65-69.	4.3	21
44	Functioning in early and late stages of schizophrenia. <i>Trends in Psychiatry and Psychotherapy</i> , 2014, 36, 209-213.	0.8	10
45	Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. <i>Neuroscience</i> , 2014, 259, 223-231.	2.3	71
46	Staging bipolar disorder: clinical, biochemical, and functional correlates. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 437-444.	4.5	84
47	Staging systems in bipolar disorder: an international society for bipolar disorders Task Force Report. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 354-363.	4.5	175
48	Differences in eotaxin serum levels patients with recent onset and in chronic stable schizophrenia: A clue for understanding accelerating aging profile. <i>Schizophrenia Research</i> , 2014, 152, 528-529.	2.0	19
49	BDNF: A biomarker for social vulnerability in individuals diagnosed with gender dysphoria. <i>Journal of Psychiatric Research</i> , 2014, 50, 16-17.	3.1	4
50	Clinical Staging in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e450-e456.	2.2	125
51	The effect of sunlight exposure on interleukin-6 levels in depressive and non-depressive subjects. <i>BMC Psychiatry</i> , 2013, 13, 75.	2.6	20
52	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1376-1382.	3.1	84
53	Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. <i>Journal of Psychiatric Research</i> , 2013, 47, 1396-1402.	3.1	92
54	Staging and Neuroprogression in Bipolar Disorder: A Systematic Review of the Literature. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 70-74.	1.7	97

#	ARTICLE	IF	CITATIONS
55	Verbal memory impairment in healthy siblings of patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 580-582.	2.0	13
56	Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine. <i>Schizophrenia Research</i> , 2013, 151, 12-19.	2.0	112
57	Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder. <i>Journal of Psychiatric Research</i> , 2013, 47, 1546-1548.	3.1	16
58	Elevated serum protein oxidative stress in siblings of patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 398-399.	2.0	7
59	Short-Term Treatment of Catatonia With Amantadine in Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 569-572.	1.4	11
60	Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls. <i>Psychiatry Research</i> , 2012, 200, 1018-1021.	3.3	15
61	Reduced serum non-enzymatic antioxidant defense and increased lipid peroxidation in schizophrenic patients on a hypocaloric diet. <i>Neuroscience Letters</i> , 2012, 512, 43-47.	2.1	6
62	Childhood trauma, impulsivity, and executive functioning in crack cocaine users. <i>Comprehensive Psychiatry</i> , 2012, 53, 238-244.	3.1	57
63	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. <i>BMC Medicine</i> , 2012, 10, 91.	5.5	81
64	Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: A study in adolescent rats with ketamine-induced model of schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 162-167.	2.0	65
65	Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. <i>Journal of Psychiatric Research</i> , 2012, 46, 819-824.	3.1	130
66	Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. <i>Neuroscience Letters</i> , 2011, 491, 207-210.	2.1	59
67	Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. <i>Neuroscience Letters</i> , 2011, 502, 143-146.	2.1	37
68	Association of biomarkers and depressive symptoms in schizophrenia. <i>Neuroscience Letters</i> , 2011, 505, 282-285.	2.1	38
69	Hypersalivation Associated with Olanzapine and Valproate Combination: A Case Report. <i>CNS Spectrums</i> , 2011, 16, 83-83.	1.2	1
70	Peripheral biomarkers and illness activity in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 156-161.	3.1	208
71	Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. <i>Journal of Psychiatric Research</i> , 2011, 45, 995-1004.	3.1	349
72	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. <i>Journal of Affective Disorders</i> , 2011, 135, 389-394.	4.1	162

#	ARTICLE	IF	CITATIONS
73	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 804-817.	6.1	1,007
74	Symptom Dimensional Approach and BDNF in Unmedicated Obsessive-Compulsive Patients: <i>An Exploratory Study</i>. <i>CNS Spectrums</i> , 2011, 16, 179-189.	1.2	22
75	Serum levels of IL-6, IL-10 and TNF- $\alpha$ ; in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 268-274.	1.7	102
76	Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. <i>Journal of Psychiatric Research</i> , 2010, 44, 561-565.	3.1	44
77	Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. <i>Journal of Psychiatric Research</i> , 2010, 44, 1158-1162.	3.1	35
78	Obesity is associated with previous suicide attempts in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 63-67.	2.1	38
79	A systemic toxicity index developed to assess peripheral changes in mood episodes. <i>Molecular Psychiatry</i> , 2010, 15, 784-786.	7.9	105
80	Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 663-665.	1.8	11
81	Mania switch induced by amantadine in bipolar disorder: report of three cases. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 467-469.	1.7	8
82	Lack of Association Between Serum Brain-Derived Neurotrophic Factor Levels and Improvement of Schizophrenia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Trial of Memantine as Adjunctive Therapy to Clozapine. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 91-92.	2.2	9
83	Estado nutricional de pacientes com esquizofrenia frequentadores do Centro de Atenção Psicossocial (CAPS) do Hospital de Clínicas de Porto Alegre. <i>Jornal Brasileiro De Psiquiatria</i> , 2010, 59, 126-130.	0.7	5
84	Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 193-194.	1.7	2
85	Molecular diversity at the <i>CYP2D6</i> locus in healthy and schizophrenic southern Brazilians. <i>Pharmacogenomics</i> , 2009, 10, 1457-1466.	1.3	30
86	Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. <i>Journal of Psychopharmacology</i> , 2009, 23, 985-987.	4.0	30
87	Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. <i>Journal of Psychiatric Research</i> , 2009, 43, 1200-1204.	3.1	111
88	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. <i>Journal of Affective Disorders</i> , 2009, 114, 1-13.	4.1	75
89	The association of child abuse and neglect with adult disability in schizophrenia and the prominent role of physical neglect. <i>Child Abuse and Neglect</i> , 2009, 33, 618-624.	2.6	69
90	Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. <i>Human Psychopharmacology</i> , 2009, 24, 233-238.	1.5	60

#	ARTICLE	IF	CITATIONS
91	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. <i>Acta Neuropsychiatrica</i> , 2009, 21, 285-291.	2.1	13
92	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. <i>Acta Neuropsychiatrica</i> , 2009, 21, 272-274.	2.1	29
93	Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. <i>Acta Neuropsychiatrica</i> , 2009, 21, 239-245.	2.1	9
94	Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. <i>Neuroscience Letters</i> , 2009, 453, 195-198.	2.1	72
95	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. <i>CNS Spectrums</i> , 2009, 14, 357-360.	1.2	53
96	Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1416-1423.	2.2	108
97	Oxidative stress may be a common mechanism linking major depression and osteoporosis. <i>Acta Neuropsychiatrica</i> , 2008, 20, 112-116.	2.1	23
98	Association of the gene encoding neurogranin with schizophrenia in males. <i>Journal of Psychiatric Research</i> , 2008, 42, 125-133.	3.1	45
99	Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. <i>Neuroscience Letters</i> , 2008, 433, 270-273.	2.1	34
100	Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. <i>Neuroscience Letters</i> , 2008, 440, 197-201.	2.1	22
101	Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1595-1598.	4.8	32
102	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1677-1681.	4.8	188
103	G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. <i>Pharmacogenomics</i> , 2008, 9, 1429-1436.	1.3	39
104	Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European and Brazilian schizophrenics. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 599-609.	1.5	38
105	Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 337-340.	1.7	28
106	Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2007, 420, 45-48.	2.1	135
107	Family-based and case-control studies reveal no association of lipocalin-type prostaglandin D2 synthase with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 642-646.	1.7	9
108	Transthyretin: No association between serum levels or gene variants and schizophrenia. <i>Journal of Psychiatric Research</i> , 2007, 41, 667-672.	3.1	8

#	ARTICLE	IF	CITATIONS
109	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 512-515.	4.8	101
110	Sobrepeso e obesidade em pacientes esquizofrênicos em uso de clozapina comparado com o uso de outros antipsicóticos. Revista De Psiquiatria Do Rio Grande Do Sul, 2006, 28, 120-128.	0.3	10
111	Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study. Revista Brasileira De Psiquiatria, 2006, 28, 339-340.	1.7	4
112	Relato do uso de clozapina em 56 pacientes atendidos pelo Programa de Atenção à Esquizofrenia Refratária da Secretaria da Saúde e do Meio Ambiente do Estado do Rio Grande do Sul. Revista De Psiquiatria Do Rio Grande Do Sul, 2004, 26, 21-28.	0.3	7
113	Increased serum S100B protein in schizophrenia: a study in medication-free patients. Journal of Psychiatric Research, 2001, 35, 11-14.	3.1	137